Schott Pharma stock weighs India IPO for local subsidiary

Published on 11/03/2026 at 13:37 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Schott Pharma stock is weighing an IPO for its Indian subsidiary, according to a November 2 report. The plan remains preliminary.

India Listing Plans Enter Focus

Schott Pharma is considering an IPO for its Indian subsidiary, according to a report published on November 2.
The potential transaction remains preliminary, with size, structure and timing still open.
The company operates in pharmaceutical glass packaging and injectable drug containment solutions.

Schott Pharma, DE000A3ENQ51, Illustration mit AI erstellt.

Schott Pharma is considering a potential initial public offering for its Indian subsidiary, according to a report by Briefs Finance published on Monday, November 2, 2026. The report said Schott Pharma had held talks with investment banks about a possible offering by Schott Pharma India Pvt.

Potential India Listing Remains Early

People familiar with the matter told Briefs Finance that the Indian subsidiary could seek a listing of as much as 400 million US dollars. The report stressed that the discussions are at an early stage, so the eventual size, structure and timing could change. Advisers had not yet been named, and the report said Schott Pharma had not responded to requests for comment.

Schott Pharma India makes pharmaceutical glass packaging for drugmakers and healthcare customers. The parent company describes its broader business as supplying containment and delivery solutions for injectable medicines, supported by a global production network and a portfolio aimed at pharmaceutical manufacturing trends, according to its investor relations overview.

Investors Await Concrete Steps

For investors, the potential listing could create a future valuation reference for the Indian business and provide a possible source of capital. No transaction has been announced, however, and the next relevant signals would be the appointment of advisers, regulatory filings or a formal statement on the offering.

Schott Pharma stock traded at 24.60 euros on Lang & Schwarz at 1:33 p.m. CET on Tuesday, November 3, 2026.

Investors can follow the real-time quote of Schott Pharma stock.

German equities remain an important backdrop for the stock, with broader market coverage available through the DAX market theme.

More developments can be found in more news and analyses on Schott Pharma stock.